Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vyome Holdings, Inc. (HIND : NSDQ)

• Company Description    Vyome Therapeutics Inc. is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases principally in the US. Vyome Therapeutics Inc., formerly known as ReShape Lifesciences Inc., is based in CAMBRIDGE, Mass. Number of Employees: 18

• Price / Volume Information    Yesterday's Closing Price: $5.51 Daily Weekly Monthly 20 Day Moving Average: 60,206 shares Shares Outstanding: 3.66 (millions) Market Capitalization: $20.16 (millions) Beta: 1.15 52 Week High: $600.00 52 Week Low: $4.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.68% 5.83% 12 Week -60.64% -62.28% Year To Date -98.76% -98.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 18 Technology Dr Suite 110 - Irvine,CA 92618 USA ph: 949-429-6680 fax: - ir@reshapelifesci.com http://www.reshapelifesciences.com

• General Corporate Information    Officers Paul F. Hickey - President and Chief Executive Officer Dan W. Gladney - Executive Chairman of the Board Thomas Stankovich - Senior Vice President and Chief Financial Officer Lori McDougal - Director Arda Minocherhomjee - Director Peer Information Vyome Holdings, Inc. (GSAC) Vyome Holdings, Inc. (CASI) Vyome Holdings, Inc. (ALCD.) Vyome Holdings, Inc. (OMNN) Vyome Holdings, Inc. (CGPI.) Vyome Holdings, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 92943X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 3.66 Most Recent Split Date: 8.00 (0.25:1) Beta: 1.15 Market Capitalization: $20.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.56 Price/Cash Flow: - Price / Sales: 3.12 EPS Growth vs. Year Ago Period: 97.42% vs. Previous Quarter: -111.85% Sales Growth vs. Year Ago Period: -36.79% vs. Previous Quarter: 11.59% ROE 09/30/25 - - 06/30/25 - -216.95 03/31/25 - -251.90 ROA 09/30/25 - - 06/30/25 - -69.42 03/31/25 - -59.49 Current Ratio 09/30/25 - - 06/30/25 - 2.77 03/31/25 - 1.53 Quick Ratio 09/30/25 - - 06/30/25 - 1.97 03/31/25 - 0.91 Operating Margin 09/30/25 - - 06/30/25 - -69.71 03/31/25 - -48.26 Net Margin 09/30/25 - - 06/30/25 - -69.71 03/31/25 - -48.26 Pre-Tax Margin 09/30/25 - - 06/30/25 - -69.33 03/31/25 - -47.82 Book Value 09/30/25 - - 06/30/25 - 9.77 03/31/25 - 10.91 Inventory Turnover 09/30/25 - - 06/30/25 - 0.92 03/31/25 - 0.93 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©